STOCKHOLM, SWEDEN - Karolinska Development AB (Nasdaq Stockholm: KDEV) has announced that its portfolio company, Umecrine Cognition, has resumed patient inclusion in its Phase 1b/2a clinical study. The study evaluates the efficacy of golexanolone, a drug candidate aimed at alleviating cognitive symptoms in patients with primary biliary cholangitis (PBC). The trial's temporary halt in March was due to technical issues in capsule production, which did not compromise patient safety.

Umecrine Cognition is at the forefront of developing innovative treatments for cognitive symptoms associated with liver diseases. Golexanolone, the company's leading drug candidate, is undergoing a rigorous randomized, double-blind, placebo-controlled study to assess its effectiveness in PBC patients suffering from significant fatigue and cognitive impairments. This development marks a critical step forward in addressing unmet medical needs in liver disease management.

Karolinska Development, holding a 73% stake in Umecrine Cognition, plays a pivotal role in nurturing Nordic life sciences innovations. The investment firm specializes in identifying and growing companies that translate breakthrough medical research into commercial products, offering both therapeutic benefits to patients and attractive returns to investors. The resumption of the clinical trial underscores the resilience and commitment of both companies to advancing healthcare solutions.

The collaboration between Karolinska Development and Umecrine Cognition exemplifies the potential of strategic investments in the life sciences sector. By leveraging world-class medical innovations and expertise, the partnership aims to bring forth treatments that could significantly improve the quality of life for patients with liver diseases. As the clinical trial progresses, the medical community eagerly anticipates the outcomes that could herald a new era in the treatment of cognitive symptoms related to liver conditions.

A violent incident at a hostel in Helsingborg has resulted in seven individuals being hospitalized, following an attack by a man in his 30s. The suspect, who fled the scene, was later apprehended with the aid of a helicopter and subdued using a taser by the police. The attack, which began inside the hostel before moving outdoors, left one person seriously injured and six others with minor injuries.

The police were alerted to the situation around 10:40 AM on Sunday. Initially, it was believed that three to four people had been assaulted. However, as the investigation progressed, the number of victims rose to seven. The suspect now faces charges including attempted murder and aggravated assault, highlighting the severity of the incident.

During the arrest, the use of a taser was necessary to subdue the suspect, who was then taken to the hospital for evaluation. The police have clarified that no weapons were used in the assault, and the incident is being investigated as cases of aggravated assault and assault. The condition of the victims varies, with one in serious condition and others sustaining minor injuries.

This incident has drawn significant attention to the safety and security measures in public accommodations and the prompt response by law enforcement in Helsingborg. The community is left shaken by the sudden violence, as authorities continue to piece together the events that led to this tragic outcome.